Cognitive Impairment Associated with Schizophrenia Providing Sensitive Assessments in Clinical Trials

Cognitive Impairment Associated with Schizophrenia Providing Sensitive Assessments in Clinical Trials

Cognitive Impairment Associated with Schizophrenia Providing Sensitive Assessments in Clinical Trials

by
72 72 people viewed this event.

Date & time

18 June 2024
2pm London | 9am New York

Location

Online webinar

Why attend?

When looking at cognitive impairment in schizophrenia, there are several clear challenges:

  • Identifying patients who would benefit from treatment
  • Determining if a new treatment for cognition impairment is successful
  • Assessing multiple cognitive domains without overburdening patients
  • The impact of fluctuating symptoms

Join this expert panel to discuss these highlighted challenges and offer solutions to scientific research in this space.

Topics will include:

  • Patient screening and stratification: patients presenting with similar symptoms and severity are identified and grouped together to enable better data analysis
  • Accurate and efficient assessment of multiple cognitive domains: simplifying and improving the patient experience to increase participant retention
  • Case study: The Potential Role of the M1/M4 Muscarinic Receptor Agonist KarXT in the Treatment of Cognitive Impairment in Patients With Schizophrenia

Speakers

Dr Francesca Cormack, Chief Scientist – Cambridge Cognition
Francesca is Chief Scientist at Cambridge Cognition. She has extensive experience of statistics, cognitive neuroscience and cognitive test development in a range of clinical populations. Since joining Cambridge Cognition in 2014, Francesca has worked to develop novel cognitive testing methodology to support high-frequency, near patient testing using digital technology, providing researchers and healthcare providers with unique insights into cognitive health. Francesca obtained a PhD in Dementia with Lewy Bodies at Newcastle University, followed by post-doctoral and academic positions at University College London and at the Medical Research Council in Cambridge. She maintains academic collaborations focused on neurological disorders, ageing and dementia.

Dr Steve Brannan, Former CMO at Karuna
Dr. Brannan is the former CMO at Karuna Therapeutics and a neuroscience drug development expert who has held senior positions overseeing both clinical development and medical affairs with more than 15 years of industry experience. Previously, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta, Exelon Patch, Trintellix, and VNS for Treatment Resistant Depression while holding various senior roles at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. His experience includes drug development, registration, medical affairs, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, migraine, cognition, and Alzheimer’s and Parkinson’s diseases. Dr. Brannan is a member of several scientific societies and groups, including ACNP, ISCTM (Member of both the Scientific and Executive Committees), ISCDD, AARR, IOM Neuroforum, and CNS Summit (founding member). Prior to joining the Pharmaceutical industry, Dr. Brannan worked on the faculty at the University of Texas Health Science Center at San Antonio (UTHSCSA) where he specialized in seeing Mood and Anxiety disorder patients, ran a clinical research unit, and did neuroimaging research at the Research Imaging Center. Dr. Brannan trained in psychiatry at UTHSCSA and holds a M.D. degree from the University of Texas Health Science Center at Dallas (Southwestern Medical School). He has over 50 publications and routinely gives invited talks and presentations at industry conferences.

Dr William Horan, Executive Director, Clinical Development – Bristol Myers Squibb
Biography coming soon!

Dr Kiri Granger, Chief Scientific Officer – Monument
Kiri is an internationally-recognised expert in the design of clinical trials for CNS disorders, particularly schizophrenia. As Director of Neuroscience at Cambridge Cognition, Kiri provided consultancy to over 50 drug development companies on more than 100 clinical trials and was the lead scientist on a number of successful programmes. Kiri chaired the ICSTM working group on schizophrenia clinical trials and is currently an Assistant Professor at the University of Nottingham, Department of Psychology where she is involved in on-going collaborations in schizophrenia and anxiety disorders.

Back to events

To register for this event email your details to ying.mak@camcog.com

Register using webmail: Gmail / AOL / Yahoo / Outlook

 

Date And Time

18 June 2024 to
18 June 2024
 

Location

Scroll to Top